Posted by Michael Wonder on 28 Feb 2018
Schedule of Pharmaceutical Benefits - 1 March 2018 update
1 March 2018 - The March 2018 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The March issue of the Schedule includes a number of new/revised listings:
- Tetracosactide (Synacthen Depot) - new indication
- Aclidinium bromide with eformoterol fumarate dihydrate (Brimica Genuair) - restriction change
- Mepolizumab (Nucala) - restriction change
- Varenicline tartrate (Champix) - restriction change
